| abstract |
Composition for photodynamic therapy comprising a photosensitiser in combination with ethylenediaminetetraacetic acid (EDTA) and epigallocatechin galate (EGCG), in pharmacologically acceptable carriers and/or excipients. The photosensitising compounds are selected from protoporphyrin IX (PpIX) precursors, such as methyl aminolevulinate (MAL) or aminolevulinic acid (ALA). These new formulations show an enhancing effect of the effect of the photosensitising compounds, MAL or ALA for example, which ensures a greater efficiency of photodynamic therapy, in the treatment of skin or mucous membranes. In one application, the invention is useful in the resolution of long-term preneoplastic or neoplastic dermatological lesions, decreasing the recurrence rates of these lesions. |